Jeff Aronin is leading the way in next generation pharmaceuticals that treat rare illnesses

Jeff Aronin has been focusing his entrepreneurial endeavors on developing new life-saving medications for previously untreatable medical conditions. For almost twenty years, Jeff has been developing novel medications through startup companies like Ovation Pharmaceuticals. Taking advantage of some of the most recent biotech breakthroughs, Mr. Aronin is helping to establish important biotechnology companies bringing treatment options to patients who previously had none available.

 

As Chairman and Chief Executive Officer of Paragon Biosciences, Jeff Aronin has been instrumental in the company’s success. To date, he and his team have successfully gotten 13 newly developed drugs approved by the FDA. When Jeff first began his career, he was assisting a physician treating a child experiencing constant seizures. Rather than doing intensive brain surgery, the physician used medicine; seeing this was enough to convince Jeff of the unique benefit pharmaceuticals can provide to suffering patients. Eventually, this would be one of the driving experiences behind Mr. Aronin’s decision to found Ovation Pharmaceuticals.

 

After selling Ovation Pharmaceuticals to Lundbeck, a Danish healthcare company, for $900 million dollars, Jeff Aronnin went on to serve as CEO of Paragon Biosciences. Throughout his tenure, he has been working on building innovative biotechnology companies focused on developing the next generation of pharmaceuticals for diseases like epidermolysis, narcolepsy, cataplexy and Alzheimer’s.

 

One of Paragon’s portfolio companies, Harmony Biosciences, is focused on creating a new line of pharmaceuticals meant to assist patients struggling with a variety of central nervous system disorders. In 2017 the company was awarded the Deal of Year by the Life Sciences Pennsylvania trade association. Another portfolio company, Castle Creek, focuses on treating patients suffering from serious dermatologic conditions. They currently have several new treatments in the late developmental stages. Recently, the company received the Partners in Progress Award for creating a topical cream focusing on helping those with epidermolysis bullosa simplex, a condition causing severe skin blisters.

 

Jeff Aronin currently serves as the non-executive chairman on a number of Praragon portfolio companies, recognized by multiple organizations for his work in the biotech industry. Winning the Frederic A Gibbs Discovery Award, Humanitarian Award and Rovner Award amongst others, Jeff has proven his commitment in funding biotech companies looking to pave the way for next-generation medicines addressing previously untreatable illnesses.

read more about jeff aronin below

https://agln.aspeninstitute.org/profile/3504

 

Leave a Reply

Your email address will not be published. Required fields are marked *